KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Total Debt (2019 - 2025)

Royalty Pharma's Total Debt history spans 7 years, with the latest figure at $9.0 billion for Q4 2025.

  • For Q4 2025, Total Debt rose 17.58% year-over-year to $9.0 billion; the TTM value through Dec 2025 reached $9.0 billion, up 17.58%, while the annual FY2025 figure was $9.0 billion, 17.58% up from the prior year.
  • Total Debt for Q4 2025 was $9.0 billion at Royalty Pharma, roughly flat from $8.9 billion in the prior quarter.
  • Across five years, Total Debt topped out at $9.0 billion in Q4 2025 and bottomed at $5.9 billion in Q1 2021.
  • The 5-year median for Total Debt is $7.2 billion (2021), against an average of $7.2 billion.
  • The largest YoY upside for Total Debt was 24.08% in 2024 against a maximum downside of 13.79% in 2024.
  • A 5-year view of Total Debt shows it stood at $7.2 billion in 2021, then fell by 1.22% to $7.1 billion in 2022, then decreased by 13.79% to $6.1 billion in 2023, then rose by 24.08% to $7.6 billion in 2024, then grew by 17.58% to $9.0 billion in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Total Debt are $9.0 billion (Q4 2025), $8.9 billion (Q3 2025), and $8.0 billion (Q2 2025).